ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.

@article{Augustyn2014ASCL1IA,
  title={ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.},
  author={Alexander Augustyn and Mark Borromeo and Tao Wang and Junya Fujimoto and Chunli Shao and Patrick D Dospoy and Victoria Lee and Christopher Tan and James P. Sullivan and Jill Everland Larsen and Luc Girard and Carmen Behrens and Ignacio Wistuba and Yang Xie and Melanie H Cobb and Adi F. Gazdar and Jane E Johnson and John D. Minna},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2014},
  volume={111 41},
  pages={14788-93}
}
Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset that accounts for approximately 40,000 new lung cancer cases per year in the United States. No targeted therapy exists for these tumors. We determined that achaete-scute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is essential for the survival of a majority of lung cancers… CONTINUE READING